

Supplemental Appendix:**1.0. Methods:**

- 1.1. CAR T-cell quantification
- 1.2. List of primers and probe used for CAR T-cell detection and quantification

2.0. Figures:

- 2.1. Timeline of clinical presentations
- 2.2. Identification of *PEX1-CDK6* fusion in case 1
 - 2.2.1. Sanger sequencing of *PEX1-CDK6* fusion

3.0. Tables:

- 3.1. Chronological review of immunophenotypic and cytogenetic evaluation of disease

1.0. Methods

We illustrate two cases from patients both treated on a Phase I study of CD22 CAR T-cells (NCT02315612), with the second patient also being involved in a Phase I study of CD19 CAR T-cells (NCT02028455) and a transplant trial incorporating use of blinatumomab on a haploidentical transplant platform (NCT02790515). All protocols were IRB approved by their respective institutions and consent and/or assent was obtained as per local guidelines.

1.1. CAR T-cell quantification

Flow cytometry was used to quantitate CD22 CAR T-cells in blood, bone marrow, and CSF using a CD22-Fc fusion protein (R&D Systems, Minneapolis, MN),⁸ and circulating CAR T-cell numbers were calculated based upon absolute lymphocyte counts. Quantification of CAR T-cell number was also carried out using Droplet Digital PCR (ddPCR) with primer/probe specific for the CAR-T lentivector and normalized to total cell number measured by primer/probe for human reference gene *MKL2* as described in Shah et al.⁷ Each CAR T-cell is assumed to carry a single integrated CAR-T lentivector. Each human cell carries 2 alleles of *MKL2* gene, and the total cell number in the input is calculated as half of the *MKL2* positive counts. Primers and probe were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA). ddPCR assay was performed using BioRad Droplet Digital PCR system (Hercules, CA) Specific primers and probe are described in Supplemental Methods.

1.2. List of primers and probe used for CAR T-cell detection and quantification

Primers:

Lentivector-Fwd specific primer: 5'CTGTTGTGTGACTCTGGTAACT3'

Lentivector probe: 5'/56-FAM/AAATCTCTA/ZEN/GCAGTGGCGCCCG/3IABkFQ/3'

Lentivector-Rev specific primer: 5'-TCGCTTTC AAGTCCCTGTTTC-3'


MKL2 Fwd primer: 5'AGATCAGAAGGGTGAGAAGAATG3'

MKL2 Rev primer: 5'GGATGGTCTGGTAGTTGTAGTG3'

MKL2 probe: 5'-/5HEX/TGTTCTGC/ZEN/AACTGCAGATCCTGA/3IABkFQ/-3'.

2.0. Figures


2.1. Timeline of clinical presentations




Abbreviations: MDS: myelodysplastic syndrome; MLDS: myeloid leukemia of Down Syndrome; CR: complete remission; ALL: acute lymphoblastic leukemia; B-ALL: B-cell ALL; MRD-CR: minimal residual disease negative CR; HSCT: hematopoietic stem cell transplant; CAR: chimeric antigen receptor; CNS: central nervous system

2.2. Identification of PEX1-CDK6 fusion in case 1

2.2.1.





CDNA

ATGTTGGGGCAGCGATCGCTGGCGGGTCTGGGGGAGGC GGGGCGGCA GTGACTGTG
 GCCTTCAACAACTCGGACTGCTTCCTCACCTGCCGCGTCTC GTGGCCAG
 CTGCATCTGCTGCAGAAACAAGCTATAGAAGTGTCTGGAGT CAC CAGCCTGCATTC
 TTGAGCTGGGTGGAAAGCAGGCATTTT AGT GATCAAGGTGAA AATGTGGCTGAAATT
 AACAGACAAGTTGGTCAAAAACCTGGACTCTCAAATGGGGGACAGGTATTTCTCAAG
 CCATGTTCCCATGTGTATCTTGTCAA CAAGTTGAGGTGGAA CCCCTCTCAGGCAGAT
 GATTTGGGAGATACTGGAGCTGCATGCTGTTTCCCTTGAA CAA CATCTTCTAGATCAA
 ATTCTGAATAGTTTCCAAAAGCCATT TTTCTGTTTGGGTTGATCAA CAAACGTAC
 ATATTTATC CAAATTGTTGACTAATACCAGCTGCTTCTTATGGAAGGCTGGAAACT
 GACACCAAACTCCTTATT CAGCCA AAGACA CGCCGAGCCAAA GAGAATACATTTTCA
 AAAGCTGATGCTGAA TATAAAAACTT CATAGTATGGAAGAGAC CAGAAAGGAATG
 ATGAAA GAACTTCAA ACCAAGCAA CTT CAGTCAAATACTGTGGGAAATC ACTGAATCT
 AATGAA AACGAGTCA GAGATTCCA GTTGACTCATCA TCA GTA GCAAGTTTA TGGACT
 ATGATAGGAAGCATT TTTTCCTTTCAA TCTGAGAAGAAA CAA GAGACATCTTGGGGT
 TTA ACTGAAATCAATGCATTCAAA AATATGCAGTCAAAGGTTGTT CCTCTAGACAAT
 ATTTTCAGAGTATGCAAA TCTCAACCTCCTAGTATA TATAACGCGTCAGCAACCCT
 GTTTTTCATAAACAC TGTGCCATT CATGATTTCCA TGGGAC CAGGAA TATTTTGAT
 GTAGAGCCCAGCTTTACTGTGACATATGGAAGCTAGTTAAGCTA CTTTCTCCAAG
 CAACAGCAAAGTAAAACAAA CAA AATGTGTTATCA CCTGAAAAGAGAAGCAGATG
 TCAGAGCCA CTAGATCAAAAAAATTAGGTCAGATCAT AATGAA GAA GATGAGAAAG
 GCC TGTGTGCTACAA GTAGTCTGGAATGGA CTTGAA GAA TTGAAC AATGCCATCAA
 TATACCAAA AATGTA GAAGTTCTC CATCTTGGGAAAGTCTGGATT CAGATGACCTG
 AGGAAGAGA CTAATATAGAAATGCATGCCGTAGTCA GAGATAACTCCA GTGGAAGTT


ACCCCTAAAATTCCAAGATCTCTAAAGTTACAACCTAGAGAGAAATTTA CCTAAAGAC
 ATAAGTGAA GAAGACATAAAA ACTGTA TTTTATTCATGGCTACAGCAGTCTACTACC
 ACCATGCTT CCTTTGTAATATCAGAGGAA GAA TTTATT AAGCTG GAAACTAAAGAT
 GGACTGAAGGAATTTTCTCTGAGTATA GTT CAT TCT TGGGAA AAA GAA AAA GATAAAA
 AATATT TTTCTGTTGAGTCCCAATTTGCTG CAGAAGACTACAATA CAA GTCCTTCTA
 GATCCTATGGTAAA GAA GAA AACAGT GAG GAAATTGAC TTTATTCTT CCTTTT TTA
 AAGCTGAGCTCTTTGGAGGAGTGAAT TCC TTAGGC GTATCC TCC TTG GAGCACATC
 ACTCACAGCCTCCTG GAGCGCCTTTG TCTCGGCAGCTGATGTCTCTT GTTGCAGGA
 CTTAGGAATGGAGCTCTTTACTCACA GGA GGAAGGGAAGT GGA AAA TCAACTTTA
 GCCAAA GCAATCTGTAAA GAAGCA TTTGAC AAACTG GATGCC CATGTG GAGAGAGTT
 GACTGTAAA GCTTTA CGAGGAAAAAGGCTT GAA AACATA CAA AAA ACCCTA GAGGTG
 GCTTTC TCA GAGGCA GTGTGGATG CAG CCA TCTGTTGTC CTGCTG GATGACCTTGAC
 CTCATTGCTGGACTG CCTGCTGTC CCGGAA CATGAGCACAGT CCTGATGCGGTGCAG
 AGCCAGCGGCTTGCTCATGCTTTGAATGATATGATAAAA GAGTTTATCTCCATGGGA
 AGTTTG GTTGC ACTGATTGCCACAAGT CAGTCTCAGCAATCTCTA CATCTTACTT
 GTTTCTGCTCAAGGAGTT CACATA TTT CAGTGC GTC CAA CACATT CAGCCTCCTAAT
 CAGGAA CAAAGATGTGAAATTCTG TGT AATGTAATAAAA AATAAA TTG GACTGTGAT
 ATAAAC AAGTTCACC GATCTTGACCTG CAGCATGTA GCTAAA GAAACTGGC GGGTTT
 GTGGCTAGA GATTTTACAGTACTTGTG GATCGAGCCATA CAT TCTCGACTCTCGT
 CAGAGTATA TCCACCAGAGAAAA TTAGTT TTAACAACA TTG GACTTC CAAAAGGCT
 CTCGCGGGA TTTCTT CCTGCGTCTTTG CGAAGTGTCAACCTG CATAAA CCTAGAGAC
 CTGGGT TGGGACAAGATTGGTGGGTTA CATGAA GTTAGG CAGATACTCATG GATACT
 ATCCAGTTA CCTGCCAAGTATCCA GAA TTA TTTGCAAAC TTG CCCATA CGACAAAGA
 ACAGGAATA CTGTTG TATGGTCCG CCTGGAACAGGAAA ACCTTA CTA GCTGGGGTA
 ATTGCA CGA GAGAGTAGAATGAAT TTTATAAGT GTC AAGGGG CCA GAGTTA CTCAGC
 AAATACATTGGAGCAAGTGAACAA GCTGTT CCGGATATT TTTATTAGAGCA CAGGCT
 GCAAAGCCCTGCATTCTT TCTTTT GATGAA TTTGAA TCCATTGCT CCTCGGCGGGT
 CATGATAATACAGGAGTTACAGACCGAGTAGTTAAC CAGTTGCTGACTCAGTTG GAT
 GGAGTAGAA GGCTTACAGGGTGT TATGTA TTGCTGCTACTAGT CGCCTGACTTG
 ATTGAC CCTGCCCTGCTTAGG CCTGGT CGACTAGATAAA TGTGTA TACTGTCTCCT
 CCTGATCAGGTGTCA CGTCTTGAAATT TTA AATGTC CTCAGT GACTCTCTA CCTCTG
 GCAGATGATGTTGACCTT CAGCATGTA GCATCAGTACTGACTCC TTTACTGGAGCT
 GATCTGAAA GCTTTA CTTTACAATGCC CAA TTG GAGGCC TTA CATGGAATGCTGCTC
 TCGAGTGGACTCCAGGATGGAAGT TCCAGC TCTGATAGT GACTAAGTCTGTCTTCA
 ATGGTCTTTCTT AACCATAGCAGTGGCTCTGACGATTCAGCTGGA GATGGA GAATGT
 GGC TTA GATCAGTCCCTT GTT TCTTTAGAGATG TCCGAGATCCTT CCA GATGAATCA
 AAATTC AATATGTAC CGGCTCTAC TTTGGAAGCTCT TATGAA TCA GAACTTGGAAAT
 GGAACC TCTTCTGATTTG GATATGATG TTT CAGCTTCTCGA GGTCTG GACTTTCTT
 CATTCA CACCGAGTAGTGCATCGC GATCTAAA CCA CAGAACATTCTG GTGACCAGC
 AGCGGACAAATAAAA CTCGCTGACTTC GGCCTTGCCCGCATC TATAGT TCCAGATG
 GCTCTAACCTCAGTG GTCGTCACGCTG TGGTACAGAGCA CCCGAA GTC TTGCTCCAG
 TCCAGCTACGCCACC CCCGTGGATCTC TGGAGTGTGGC TGCATA TTTGCA GAAATG

TTTCGTAGAAAGCCTCTTTTTCGTGGAAGTTCAGATGTTGATCAACTAGGAAAAATC
 TTGGACGTGATTGGA CTC CCAGGA GAA GAAGACTGG CCTAGA GATGTTGCCCTTCCC
 AGGCAGGCTTTTCAT TCAAAA TCTGCC CAACCAATTGAGAAG TTTGTAACGATATC
 GATGA ACTA GGC AAA GACCTACTTCTGAAGTGT TTTGACATTTAACCCAGCCAAAAGA
 ATATCTGCC TACAGT GCCCTGTCTCAC CCATACTTC CAGGACCTG GAAAGGTGCAA
 GAAAACCTG GATTCC CACCTGCCG CCCAGC CAGAACACCTCG GAGCTGAATACAGCC
 TGA

Protein

MWGS DRLAGAGGGGAAV **TVAF**TNARD**CF**LHL**PRRLVAQLHLLQ**NQAIEV**VWS**HQP**AF**
LSWVEGRHFSDQEN**VAEINRQVGQKLGLS**NGG**QVFLKPCS**-H**VVSCQ**-**QVEVEPLSA**
DDWEILEL**HAVSLEQHLLDQIRIVFPKAI**FPV**WVDQQTYIFIQ**IVAL**IPAASYGRLE**
TDTKLLIQP-K**TRRA**KENT**FSKADAEYK**KLHSYGRD**QKGM**KE**LQTKQL**QSN**TVGITE**
 S**NE**NESEI**PVDSSSVASL**WTMIGSIF**SFQSEKKQETS**WGLTEIN**AFKNMQSKV**VPLD
 N**IFR**VCK**SQPPSIYNASATS**VF**HKHCAIHVFP**WDQ**EYFDVEPSFTV**TY**GKLVKLLSP**
 K**QQQSKTKQ**NVLS**PEKEKQ**MSEPLD**QKKIRSDHNEE**DEKACV**LQVVWNGLEEL**NNAI
 KY**TKN**VEVL**LHLGK**VWIP**DDL**RKRLNIEM**HAVVRI**TP**VEVTPKI**PRSL**LQPRE**NLPK
 DI**SEEDIK**TVF**YSWLQ**QST**TTMLPLVI**SE**EFIKLE**TKDGL**KEFSL**SIVHS**WEKEKD**
 K**NI**FLL**SPNLLQ**KT**TIQVLLD**PMV**KEENSEE**IDF**ILPFLKLS**SLGG**VNSLGVSSLEH**
 I**THSLLGRPLSR**QLMS**LVAGLR**NG**ALLTGGKGS**GK**STLAKAICKEAF**DK**LDAHVER**
VDCKALRGRLENI**QKTI**-E**VAFSEAVWMQPSV**VLLD**DLDIAGLPAVPE**HEH**SPDAV**
 Q**SQRLA**HALND**MIKEFIS**MGSL**VALIATSQSQ**SL**HPLL**VSA**QGVHIFQCVQ**HI**QPP**
 N**QEQR**CEIL**CNVIK**NK**LDCDINKFTDL**DL**QHVAKETGGF**VARD**FTVLVDRAI**HS**RLS**
 R**QSI**STRE**KLVLT**TLDF**QKALR**GFL**PASLR**SVNL**LHKPRDLG**WDKI**GGLHEVRQ**ILMD
 TI**QLPAKYP**ELFAN**LPIRQRTGI** **LLYGPPGTGKTLLAGV**IARE**SRMNFISVKGP**EL-L
 SKYIG**ASEQAVR**DI**FIRAQA**AK**PCILFFDEFESI**APRR**GH**DNT**GV**TD**RVVNQ**LL**TQL**
 DG**VEGLQGVY**VLA**ATSRPDLID**PALL**RPGRLDKCVYC**PPD**QVSRLEILNVLS**DSL**P**
 L**ADDVDLQ**HVAS**VTDSFTGADL**KALLY**NAQLEALHGMLLSSGLQD**GSSSS**SDSL**SLS
 SM**VFLNHSSG**SDS**AGDGE**CGLD**QSLVSLEMSEILP**DESK**FNM**YR**LYFGSSYE**SELG
 NGT**SSDI**DMM**FQLLRGLDFLH**SR**VVHRDLK**PON**ILVTSSGQIKLAD**FGL**ARIYSFO**
MALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFR-**RKPLFRGSSD**DVD**QLGK**
 I**LDVIGL**PG**EEDWPRD**VAL**PRQAFH**SK**SAQPIEK**F**VTDI**DEL**GKDLLKCLTF**N**PAK**
 R**ISAYSALSH**PY**FQDLER**CKEN**LD**SH**LPPSQNTSEL**NTA*

2.2.2. Sanger sequencing of PEX1-CDK6 fusion



3.0. Tables

3.1. Chronological review of immunophenotypic and cytogenetic evaluation of disease

Case 1				
Months from Initial Diagnosis	Diagnosis	Disease Sites	Immunophenotype	Cytogenetics
At Diagnosis	MDS	Bone marrow	N/A	Normal by conventional karyotyping
8	B-ALL	Bone marrow	N/A	t(5;15)(q3;q15) FISH showed relocation of intact <i>PDGFRB</i> from 5q to 15q, consistent with the t(5;15), but with no <i>PDGFRB</i> rearrangement. There was no evidence of <i>PDGFRA</i> , <i>PDGFRB</i> or <i>FGFR1</i> gene rearrangements by interphase FISH.
80	B-ALL (2 nd relapse, post-HSCT)	Bone marrow	CD45 (>95%), CD19 (89%) , CD10 (81%), CD22 (90%) , CD20 (41%), TdT (88%), CD33 (9%), CD34 (10%), CD10 (81%), CD117 (3%), CD14 (7%), CD13 (7%), CD2 (2%), CD4 (7%), CD3 (<1%), CD8 (8%), CD64 (6%), HLA-DR (93%), CD7 (<1%), MPO (7%)	45~49,XY,2,add(2)(p16),add(3)(q12),t(5;15)(q3;q15),+6,add(8)(p1),9,l(9)(q10),+11,add(11)(p1),add(12)(p1),add(16)(p13),add(16)(p13),add(16)(p13),add(17)(p1),add(19)(q1),+21c,+2~3mar[cp5]/46,XX[7]
87	B-ALL (3 rd relapse, post-second round of blinatumomab)	Bone marrow, left temporal bone	CD22 (>99%) , CD10, bright CD24, moderate CD38, dim CD45, intracellular CD79a, dim CD20, dim CD81 CD19 negative , CD34/CD15/CD123 negative	N/A
99	B-ALL (post-first round of CD22 CAR therapy)	Paraspinal/spinal canal lesions	Bright CD19 (100%) , CD22 (>99% positive) , moderate to bright CD10,	N/A

		(T10-12, L4-L5), CSF	CD38, partialCD24 (38% positive), dim CD45 CD34 negative	
110	B-ALL (post-second round of CD22 CAR therapy) AML (myeloid sarcoma)	ALL: Central spinal cord (C7, T8, L1, L3), CSF AML: left inferior peri- orbital soft tissue	ALL: CD19 positive , moderately dim CD38, partialCD45 CD22 negative , CD10/CD11b/ CD13/CD14/CD15/CD24/ CD34/CD36/CD64 negative AML: moderate CD45, bright HLA- DR, CD38, dim to negative CD13, dim CD33, MPO positive CD19 negative, CD22 negative , CD3/CD10/CD14/CD16/CD24/CD34/ CD56/CD66b/CD79a/CD117 negative, TdT negative	<i>PEX1-CDK6</i> fusion (identified by RNAseq, confirmed by Sanger sequencing)
Case 2				
Months from Initial Diagnosis	Diagnosis	Disease Sites	Immunophenotype	Cytogenetics
At Diagnosis	B-ALL	Bone marrow	N/A	N/A
63	B-ALL (3 rd relapse)	Bone marrow	CD19 positive (>99%), CD22 positive (99%) , CD24, bright CD10, dim to negative CD34, dim to negative CD38, dim CD45, bright CD13 CD3/CD14/CD16/CD56 negative	45,X,- X,add(4)(p14),der(8;12)(q10;q10),?add(9)(p13),- 16,?add(21)(q22),+2mar[12]/46,XY[8] Positive for loss of the <i>CDKN2A</i> locus (also known as p16) in 91.5% of cells. Positive for a translocation between chromosomes 12 and 21 in 99.5% of cells (<i>ETV6-RUNX1</i>). Negative for a translocation between chromosomes 9 and 22.

				Negative for loss or rearrangement of 11q23. ISCN: 46,XY,?inv(17)(p11.2q11.2) or ?dup(17)(q11.2) or ?ins(17;?)(q11.2;?)[3]/46,XY[17] nuc ish(DXZ1x1)[3/507]/(DXZ1x2)[6/507]/(DXZ1,DYZ1)x1[498/507]
70	B-ALL (Relapse post-CD22 CAR therapy)	Bone marrow, pancreatic head, spleen, mesentery, medial left breast	CD19 positive (100%), CD22 positive (100%) , bright CD24, bright CD10, spectrum of CD34 from moderate to negative (predominantly negative), dim CD38, dim CD45, bright CD13 CD3/CD14/CD16/CD20/CD56 negative	N/A
72	B-ALL (Prior to CD19 CAR therapy) Donor-derived MDS	Bone marrow, bilateral breasts, bilateral ovaries, parietal bone, skeletal involvement	CD19 positive , CD10, CD33 (majority positive, dim), CD38, CD45 (dim), CD58, CD71 CD2/CD13/CD14/CD20/CD34 negative	45,XY,-7[10] //46,XY[10] ISCN FISH result: ish t(12;21)(p13;q22)[10/25]/-7(D7Z1-,D7S486-)[9/24].nuc ish(ETV6x2,RUNX1x3)(ETV6 con RUNX1x1)[51/100]/(D7Z1,D7S486)x1[6/100] Summary: There are two unrelated abnormal clones in the current bone marrow specimen. The clone with the <i>ETV6-RUNX1</i> rearrangement from this patient's B-cell leukemia is still present. In addition, a clone with monosomy 7 is now present in cells of <u>donor</u> origin.
88	Acute leukemia of ambiguous lineage (T/myeloid, post-	Bone marrow, bilateral axilla/breasts	CD3 positive (cytoplasmic), CD33, CD34, CD117, CD133, MPO (subset)	Post-CD19 CAR cytogenetics:

	CD19 CAR therapy and HSCT)		CD19 negative. CD5/CD11c/CD14/CD13/CD123 negative	ISCN result: //46,X,-Y,+8[5] //45,XY,-7[5] //46,XY[10] Result Summary: There are two abnormal clones present in cells of <u>donor</u> origin: one with monosomy 7 and one with trisomy 8 and loss of Y. Relapse post-HSCT cytogenetics: Cytogenetics: 2 populations Patient derived - <i>ETV6-RUNX1</i> Patient derived - <i>ETV6-RUNX1</i> with delXq
Abbreviations: MDS: myelodysplastic syndrome; ALL: acute lymphoblastic leukemia; B-ALL: B cell ALL; FISH: fluorescence in situ hybridization; HSCT: hematopoietic stem cell transplant; CAR: chimeric antigen receptor; CSF: cerebrospinal fluid; AML: acute myeloid leukemia; N/A: not available				